Color's Low-Cost Hereditary Cancer Risk Panel Garners In-Network Status With Several Insurers

NEW YORK (GenomeWeb) – When Color launched two years ago, its next-generation sequencing test gauged 19 genes associated with breast and ovarian cancer, and the company priced it at one-tenth the cost of other comparable panel tests, betting that there would be a substantial demand from individuals interested in learning their risk for these diseases who didn’t fit insurers’ criteria.

Color’s NGS panel now gauges 30 genes associated with the risk of eight common hereditary cancers, but the price has remained what it was at launch: $249. The company announced today that starting June 15, the low-cost test will be covered as an in-network test option by several insurers, including UnitedHealthcare, Anthem, and Blue Shield of California, when enrollees meet certain criteria around personal and family history of cancer.

“Color is a self-pay option and has been since we’ve launched, although we’ve received a large number of requests from providers to cover patients who do typically meet insurers’ criteria,” Darrin Crisitello, Color’s VP of global sales and marketing, said in an interview. “We wanted to go down that route, and when we spoke to insurers and payors, our price point really resonated with them.”

The company is planning to continue

Be the first to comment

Leave a Reply

Your email address will not be published.